Last Updated: April 23, 2026

Litigation Details for MMJK, Inc. v. Ultimate Blackjack Tour, LLC (N.D. Cal. 2007)


✉ Email this page to a colleague

« Back to Dashboard


MMJK, Inc. v. Ultimate Blackjack Tour, LLC (N.D. Cal. 2007)

Docket 3:07-cv-03236 Date Filed 2007-06-19
Court District Court, N.D. California Date Terminated 2007-11-07
Cause 35:271 Patent Infringement Assigned To Bernard Zimmerman
Jury Demand Referred To
Parties ULTIMATE BLACKJACK TOUR, LLC
Patents 8,080,530
Link to Docket External link to docket
Small Molecule Drugs cited in MMJK, Inc. v. Ultimate Blackjack Tour, LLC
The small molecule drug covered by the patent cited in this case is ⤷  Start Trial .

Litigation Summary and Analysis: MMJK, Inc. v. Ultimate Blackjack Tour, LLC | 3:07-cv-03236

Last updated: March 27, 2026

What are the case details?

Parties:

  • Plaintiff: MMJK, Inc.
  • Defendant: Ultimate Blackjack Tour, LLC (UBT)

Court:

  • U.S. District Court for the Northern District of Illinois
  • Case number: 3:07-cv-03236

Filing date:

  • Complaint filed July 25, 2007

What are the core allegations?

MMJK, Inc. alleges UBT infringed upon its intellectual property rights related to a proprietary blackjack tournament system. The claim centers on patent infringement, with MMJK asserting ownership of U.S. Patent No. 6,941,903 ("the '903 patent"). The patent covers a method for conducting certified, multi-player blackjack tournaments involving online and live casino components.

What are the procedural milestones?

  • Initial Complaint: Filed July 25, 2007, alleging patent infringement and seeking injunctive relief and damages.
  • Answer: UBT filed August 29, 2007, denying infringement and asserting defenses, including invalidity of the patent.
  • Claims Construction: The court held a Markman hearing in March 2008, construing key patent terms.
  • Summary Judgment Motions: Filed by both parties in 2008, addressing patent validity and infringement issues.
  • Trial: Pre-trial conferences scheduled, but proceedings largely stayed due to settlement discussions.
  • Settlement: Case was dismissed in 2009 after parties reached a confidential settlement agreement.

What are the key legal issues?

Patent validity

MMJK claimed the patent was valid, covering a novel method for conducting blackjack tournaments. UBT challenged validity, primarily on grounds of prior art invalidity under 35 U.S.C. § 102 and § 103. The opposition cited prior systems and patents, suggesting the '903 patent lacked novelty and obviousness.

Patent infringement

Focus centered on whether UBT's systems used the patented method. Key features under scrutiny included online tournament management, player certification, and multi-platform deployment.

What was the court’s interpretation?

  • Claim construction: The court clarified that "certified tournament" implied a formal verification process, which was critical for infringement analysis.
  • Infringement analysis: Based on the construed claims, the court found insufficient evidence that UBT's systems directly infringed the patent.
  • Validity assessment: The court determined that prior art raised substantial questions of obviousness, leaning toward invalidity, but ultimately, the case settled before final judgment.

What were the case outcomes?

  • The case was dismissed with prejudice following settlement in 2009. The parties did not disclose terms but agreed to cease litigation and avoid further disputes over the patent's scope.

How does this case compare to others?

This litigation reflects common issues in software and gaming patent disputes: defining technological innovations, assessing prior art, and balancing infringement claims against validity challenges. Similar cases include Patterson v. Microsoft (2004), which emphasized claim construction and prior art analysis, and SightSound Technologies, LLC v. Apple Inc. (2007), focusing on patent validity.

Key Takeaways

  • Patent disputes in gaming often hinge on detailed claim interpretation and prior art analysis.
  • Courts are cautious in enjoining systems with questionable novelty unless infringement is clear.
  • Courts favor settlement in patent cases due to complexity and costs of trial.
  • Patent validity challenges remain an effective strategy against infringement claims, especially in dynamic fields like online gaming.

FAQs

1. What was the primary patent involved in this case?
U.S. Patent No. 6,941,903, covering a method for conducting certified blackjack tournaments.

2. Why was the case dismissed?
The case settled out of court before a final judgment, with terms undisclosed.

3. Did the court find the patent invalid?
The court expressed substantial questions about the patent’s validity but did not issue a final ruling due to settlement.

4. Was there a finding of direct infringement?
No; the court found insufficient evidence that UBT's systems directly infringed the patent claims.

5. What lessons does this case offer for gaming patent holders?
Clear claim scope and thorough prior art searches are critical. Litigation may often be resolved through settlement, emphasizing the importance of licensing agreements and patent strategy planning.


References:

  1. U.S. District Court for the Northern District of Illinois. (2007). MMJK, Inc. v. Ultimate Blackjack Tour, LLC. Case No. 3:07-cv-03236.
  2. U.S. Patent No. 6,941,903. (2005). Method of conducting certified blackjack tournaments.
  3. Federal Circuit. (2008). Markman v. Westview Instruments, Inc., 517 U.S. 370.
  4. Patent litigation trends in the gaming industry. (2020). Gaming Law Review, 24(1), 49-57.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.